These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 719009)

  • 1. Preparation and properties of biologically active fluorescent heparins.
    Nagasawa K; Uchiyama H
    Biochim Biophys Acta; 1978 Dec; 544(2):430-40. PubMed ID: 719009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation of biologically active fluorescent heparin composed of fluorescein-labeled species and its behavior to antithrombin III.
    Uchiyama H; Nagasawa K
    J Biochem; 1981 Jan; 89(1):185-92. PubMed ID: 6783633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation and properties of fluorescent glycosaminoglycuronans labeled with 5-aminofluorescein.
    Ogamo A; Matsuzaki K; Uchiyama H; Nagasawa K
    Carbohydr Res; 1982 Jul; 105(1):69-85. PubMed ID: 7116357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulant properties of heparin preparations from different animal sources with equivalent high affinity for antithrombin III.
    Nagasawa K; Uchiyama H
    J Biochem; 1984 Mar; 95(3):619-26. PubMed ID: 6725227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A fluorescent probe assay (Heparin Red) for direct detection of heparins in human plasma.
    Warttinger U; Giese C; Harenberg J; Holmer E; Krämer R
    Anal Bioanal Chem; 2016 Nov; 408(28):8241-8251. PubMed ID: 27655335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural basis for the anticoagulant activity of heparin. 2. Relationship of anticoagulant activity to the thermodynamics and fluorescence fading kinetics of acridine orange-heparin complexes.
    Menter JM; Hurst RE; Corliss DA; West SS; Abrahamson EW
    Biochemistry; 1979 Oct; 18(20):4288-92. PubMed ID: 486425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contribution of chemical 6-O-sulfation of the aminodeoxyhexose residues in whale heparin with high affinity for antithrombin III to its anticoagulant properties.
    Uchiyama H; Metori A; Ogamo A; Nagasawa K
    J Biochem; 1990 Mar; 107(3):377-80. PubMed ID: 2341372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemical microdetermination of heparin in plasma.
    Toida T; Huang Y; Washio Y; Maruyama T; Toyoda H; Imanari T; Linhardt RJ
    Anal Biochem; 1997 Sep; 251(2):219-26. PubMed ID: 9299019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of N-deacetylation and N-desulfation of heparin on its anticoagulant activity and in vivo disposition.
    Bjornsson TD; Schneider DE; Hecht AR
    J Pharmacol Exp Ther; 1988 Jun; 245(3):804-8. PubMed ID: 3164387
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of affinity for antithrombin III by supplemental sulfation of heparin species with low affinity for the protein.
    Ogamo A; Metori A; Uchiyama H; Nagasawa K
    J Biochem; 1990 Oct; 108(4):588-92. PubMed ID: 2292586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects on platelets and on the clotting system of four glycosaminoglycans extracted from hog mucosa and one extracted from aortic intima of the calf.
    Cella G; Scattolo N; Luzzatto G; Stevanato F; Vio C; Girolami A
    J Med; 1986; 17(5-6):331-46. PubMed ID: 2953835
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N.m.r. spectroscopic observations related to the function of sulfate groups in heparin. Calcium binding vs. biological activity.
    Ayotte L; Perlin AS
    Carbohydr Res; 1986 Jan; 145(2):267-77. PubMed ID: 3955564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fractionation and structural features of two heparin families with high antithrombotic, antilipemic and anticoagulant activities.
    Bianchini P; Osima B; Parma B; Nader HB; Dietrich CP; Casu B; Torri G
    Arzneimittelforschung; 1985; 35(8):1215-9. PubMed ID: 4074437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth inhibition in vitro of murine mammary adenocarcinoma cells by heparin and chemically modified heparins.
    Bertolesi GE; Lauría de Cidre L; Eiján AM
    Tumour Biol; 1994; 15(5):275-83. PubMed ID: 7991988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Determination of anticoagulant activity of heparin].
    Dalmora SL; Assaf GS; Dalmora ME; Vaucher LC; Vaccari SF
    Rev Hosp Clin Fac Med Sao Paulo; 1991; 46(2):59-62. PubMed ID: 1843369
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heparin elimination in uraemic patients on Haemodialysis.
    Teien AN; Bjoornson J
    Scand J Haematol; 1976 Jul; 17(1):29-35. PubMed ID: 959771
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Fluorescent Probe for Glycosaminoglycans Applied to the Detection of Dermatan Sulfate by a Mix-and-Read Assay.
    Rappold M; Warttinger U; Krämer R
    Molecules; 2017 May; 22(5):. PubMed ID: 28486420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a new potent heparin. 1 communication: Determinations of anticoagulant activity of a high potency heparin preparation in vivo using dog as an experimental animal and in vitro using dog and human plasma.
    Bhargava AS; Heinick J; Schöbel C; Günzel P
    Arzneimittelforschung; 1980; 30(6):993-6. PubMed ID: 7191280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates.
    Casu B; Johnson EA; Mantovani M; Mulloy B; Oreste P; Pescador R; Prino G; Torri G; Zoppetti G
    Arzneimittelforschung; 1983; 33(1):135-42. PubMed ID: 6219676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV type 1 properties of chemically modified heparins with diminished anticoagulant activity.
    Lopalco L; Ciccomascolo F; Lanza P; Zoppetti G; Caramazza I; Leoni F; Beretta A; Siccardi AG
    AIDS Res Hum Retroviruses; 1994 Jul; 10(7):787-93. PubMed ID: 7986584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.